Pharmaceutical

ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia

Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.

Jun 3, 2025 - 06:00
ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia
Nplate improved platelet response and reduced therapy modification for patients with chemotherapy-induced thrombocytopaenia.
Read the original article

Tags:

Previous Article

Regeneron to acquire rights for Hansoh’s HS-20094 therapy

Next Article

BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Do GLP-1s have a future treating alcoholism?

STAT+: Do GLP-1s have a future treating alcoholism?

Dec 3, 2023

Bristol Myers Squibb’s Breyanzi receives EC approval to treat LBCL

Bristol Myers Squibb’s Breyanzi receives EC approval to...

May 4, 2023

Rare-disease doctors support expanded newborn genomic screening, survey finds

Rare-disease doctors support expanded newborn genomic s...

May 9, 2023